The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells
Open accessAbstract
De novo and acquired resistance to the anti-tumour drug gefitinib (ZD1839; Iressa), a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) has been reported. We have determined whether signalling through the IGF-I receptor (IGF-1R) pathway plays a role in the gefitinib-acquired resistance phenotype. Continuous exposure of EGFR-positive MCF-7-derived tamoxifen resistant breast cancer cells (TAM-R) to 1 μM gefitinib resulted in a sustained growth inhibition (90%) for 4 months before the surviving cells resumed proliferation. A stable gefitinib-resistant subline (TAM/TKI-R) was established after a further 2 months and this showed no detectable basal phosphorylated EGFR activity. Compared with the parental TAM-R cells, the TAM/ TKI-R cells demonstrated (a) elevated levels of activated IGF-1R, AKT and protein kinase C (PKC)δ, (b) an increased sensitivity to growth inhibition by the IGF-1R TKI AG1024 and (c) an increased migratory capacity that was reduced by AG1024 treatment. Similarly, the EGFR-positive androgen-independent human prostate cancer cell line DU145 was also continuously challenged with 1 μM gefitinib and, although substantial growth inhibition (60%) was seen initially, a gefitinib-resistant variant (DU145/TKI-R) developed after 3 months. Like their breast cancer counterparts, the DU145/TKI-R cells showed increases in the levels of components of the IGF-1R signalling pathway and an elevated sensitivity to growth inhibition by AG1024 compared with the parent DU145 cell line. Additionally, DU145/TKI-R cell migration was also decreased by this inhibitor. We have therefore concluded that in breast and prostate cancer cells acquired resistance to gefitinib is associated with increased signalling via the IGF-1R pathway, which also plays a role in the invasive capacity of the gefitinib-resistant phenotype.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
A rapid in vitro assay for quantitating the invasive potential of tumor cells.
Albini, A., Iwamoto, Y., Hk, K., Gr, M., Aaronson, S. A., Jm, K., & McEwan, R. N. (1987) · PubMed · Cited by 1,778
Role of the Insulin-Like Growth Factor Family in Cancer Development and Progression
Yu, H. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.18.1472 · Cited by 1,424
Protein Kinase C Isotypes Controlled by Phosphoinositide 3-Kinase Through the Protein Kinase PDK1
Le Good, J. A., Ziegler, W. H., Parekh, D. B., Alessi, D. R., Cohen, P., & Parker, P. J. (1998) · Science · doi:10.1126/science.281.5385.2042 · Cited by 1,110
Breast Cancer Research and Treatment
Alexander, M. (1999) · Breast Cancer Research and Treatment · doi:10.1023/a:1006151427889 · Cited by 997
A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.
Ciardiello, F., & Tortora, G. (2001) · PubMed · Cited by 977
Protein kinase C - a question of specificity
Dekker, L. V., & Parker, P. J. (1994) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(94)90038-8 · Cited by 944
Ciardiello, F., Caputo, R., Bianco, R., Damiano, Pomatico, G., De Placido, S., Bianco, A. R., & Tortora, G. (2000) · PubMed · Cited by 943
Isolation of a human prostate carcinoma cell line (DU 145)
Stone, K. R., Mickey, D. D., Wunderli, H., Mickey, G. H., & Paulson, D. F. (1978) · International Journal of Cancer · doi:10.1002/ijc.2910210305 · Cited by 926
Cited by
Belfiore, A., Frasca, F., Pandini, G., Sciacca, L., & Vigneri, R. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0047 · Cited by 1,033
Zinc as a Gatekeeper of Immune Function
Wessels, I., Maywald, M., & Rink, L. (2017) · Nutrients · doi:10.3390/nu9121286 · Cited by 747
The role of insulin receptors and IGF-I receptors in cancer and other diseases
Frasca, F., Pandini, G., Sciacca, L., Pezzino, V., Squatrito, S., Belfiore, A., & Vigneri, R. (2008) · Archives of Physiology and Biochemistry · doi:10.1080/13813450801969715 · Cited by 410
Law, J. H., Habibi, G., Hu, K., Masoudi, H., Wang, M. Y. C., Stratford, A. L., Park, E., Gee, J. M. W., Finlay, P., Jones, H. E., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2755 · Cited by 401
Self-citationMorgillo, F., Woo, J. K., Kim, E. S., Hong, W. K., & Lee, H.-Y. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1684 · Cited by 338
Metadata
- Authors
- Jones, H. E., Goddard, L., Gee, J. M. W., Hiscox, S., Rubini, M., Barrow, D., Knowlden, J. M., Williams, S., Wakeling, A. E., & Nicholson, R. I.
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2004-12
- Volume
- 11
- Issue
- 4
- Pages
- 793-814
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2005631145
- Cited by
- 297
- References
- 41
- FWCI
- 8.96
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. https://app.cochat.ai/papers/10.1677/erc.1.00799
- The paper
- Jones, H. E., Goddard, L., Gee, J. M. W., Hiscox, S., Rubini, M., Barrow, D., Knowlden, J. M., Williams, S., Wakeling, A. E., & Nicholson, R. I. (2004). Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocrine-Related Cancer. https://doi.org/10.1677/erc.1.00799
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.